Good news always comes out faster than bad news!
Like the rest of the market, I was looking for the Scottish-based housebuilding and construction group Springfield Properties (LON:SPR) to announce its Interim Results for the six months to end-November 2024 tomorrow morning, as planned.
However, the group declared them this morning – they were good and better than expected.
The group also announced that its is selling 2,480 of its building plots to Barratt Redrow for £64.2m.
Together those two pieces of news should be positive enough to push the shares forward again.&nbs...
Anglo American outlines platinum unit demerger timeline
Mining giant Anglo American has outlined its June timeline for the separation of Anglo American Platinum, following the platinum company’s release of its 2024 annual results.
Anglo American has scrambled to fight off takeover interest from BHP, and this demerger is one measure undertaken in an attempt to keep the Anglo listing going.
The unit will be listed on both the Johannesburg Stock Exchange and the London Stock Exchange, meaning the London-listed AAL entity will retain some exposure to its platinum business.
Anglo American Platinum has declared dividends amounting to R16.5 billion (approximately £0.7 billion), which comprises both a final dividend for 2024 and an additional cash dividend.
These payments will be distributed to all shareholders before the demerger takes place. As Anglo American currently holds approximately 67 per cent of Anglo American Platinum’s shares, it anticipates receiving roughly £0.5 billion from these dividend payments.
Anglo American Platinum reported adjusted EBITDA for 2024 of R19.8 billion, approximately $1.1 billion.
“We are on a clear timeline towards demerging Anglo American Platinum – the world’s leading PGMs producer – in June, with its primary listing on the Johannesburg Stock Exchange and an additional listing on the London Stock Exchange,” said Duncan Wanblad, Chief Executive of Anglo American.
“Consistent with our commitment to deliver a responsible demerger, Anglo American intends to retain a 19.9% shareholding in Anglo American Platinum in order to further help manage flowback by reducing the absolute size of the shareholding that will be demerged. Anglo American will no longer have any representation on the Anglo American Platinum board post demerger and we intend to exit our residual shareholding responsibly over time, and subject to customary lock-up arrangements.”
AIM weekly movers: Xeros Technology shares continue to rebound
Sustainable laundry technology developer Xeros Technology (LON: XSG) is among the top AIM performers for a second week. Non-exec Klaas de Boer bought 3 million shares at 0.82p each and fellow non-exec David Armfield bought 2.6 million shares at 0.7602p each. Dowgate has increased its shareholding from 11.4% to 13.2%. The estate of William Black has cut its stake from 8.93% to 5.24%. Two weeks ago, Xeros Technology said that it is progressing with tech verification from four global washing machine manufacturers and two of those could move to substantial paid-for joint development agreements. Timing is uncertain, though. The share price recovered a further 73.3% to 1.3p – compared with 0.525p a fortnight ago.
Iron replacement treatment developer Shield Therapeutics (LON: STX) continued its share price recovery last week with a 35% gain to 4.05p, having been 2.8p two weeks ago. This follows the announcement that 2024 revenues were $32.2m as ACCRUFeR sales in the US build up. Management is optimistic that there is enough cash to get to cash flow positive by the end of 2025. Chief executive Anders Lundstrom bought 575,000 shares at 3.7p each, taking his stake to 585,000 shares.
Light Science Technologies (LON: LST) has signed an agreement with Gavita subsidiary Agrolux Nederland to distribute its horticulture lighting products. The deal initially covers the UK and Ireland. Agrolux will sell Light Science Technologies products through its distributor network. Daniel Holliday increased his stake from 10% to 11%. There will be a capital markets day on 26 February. The share price improved 29.4% to 3.3p.
Serinus Energy (LON: SENX) has won a legal case against the Romanian tax authorities over VAT refunds. The company has been awarded a VAT refund of $1.73m for 2018 and 2019, as well as interest of $750,000. This has to be paid within 45 days. The Romanian operation is loss-making, but there are gas projects that could be developed. The 2024 results are due to be published in March and there should be news concerning how the money will be invested in the business. The share price is 18.7% higher at 2.85p, having been 3.25p earlier on Friday.
FALLERS
Immunodiagnostics developer Oncimmune (LON: ONC) increased revenues by 140% to £2.7m in the 12 months to August 2024. The loss was reduced from £3.9m to £3.2m. Cash was more than £1m at the end of January 2025 with £1.5m of debt outstanding. Strategic partnerships are being explored and additional finance will be sought. The share price slumped 56% to 4p.
Canaccord Genuity reduced its stake in online building products retailer CMO Group (LON: CMO) from 5.37% to 4.31%. The share price slid 55.8% to a new low of 4.25p.
Lord Ashcroft is trying to remove another of his companies from AIM. A general meeting has been requisitioned at wine maker Gusbourne (LON: GUS), where he owns 66.8%. Talks with potential acquirers have ended and the strategic review has been terminated. This follows Lord Ashcroft’s success in getting Merit Group and Jaywing to leave AIM. The share price dived 51.3% to 18.5p.
Drug mathematical modelling company Physiomics (LON: PYC) has raised £430,000 at 0.5p/share and could raise up to £70,000 more from a WRAP retail offer. The offer closes on 17 February. This will finance the expansion of a consulting service and market the biostatistics. It will also fund exploration of a deeper relationship with DoseMe to develop models for its platform. The share price slipped 38.2% to 0.525p.
Aquis weekly movers: All Things Considered for Main Market switch
Ormonde Mining (ORM) has secured three-year renewals for two gold exploration licences in Zamora Province in western Spain. Ormonde Mining plans to acquire the other 51.3% interest in the licences from AIM-quoted cyber security company Shearwater Group (SWG) for five million shares. That is a discount to the implied book value. The Ormonde Mining share price dipped 17.2% to 0.17p.
Music management and event promotion company All Things Considered (ATC) more than doubled 2024 revenues to £50m and EBITDA was £1.5m. Growth is coming from adding managers and new clients, plus acquisitions. Further acquisitions are planned. An agreement has been reached to take the stake in livestreaming platform Driift from 32.5% to 100%. All Things Considered is assessing a move to an unspecified London Stock Exchange market. The share price rebounded 7.69% to 105p.
EDX Medical (EDX) has appointed Martin Walton as deputy chair. He has worked for other life sciences companies, including former AIM company ReNeuron. The share price rose 5.56% to 9.5p.
In the year to January 2025, EPE Special Opportunities (EO.P) NAV edged up to 328p/share. That includes cash of £11m. Trading was tough for all of the businesses in the portfolio. Investee company Whittard of Chelsea increased like-for-like sales by 6%. Pharmacy2U also grew organically and acquired a business in the pet care market. The share price improved 3.33% to 155p.
FALLERS
Inteliqo Ltd (LON: IQO) wants to cancel the admission to the Aquis Stock Exchange. Inteliqo has been developing and marketing the Langaroo app for a client. It wants to save the costs of the quotation. Trading could end on 14 March if shareholders agree at the general meeting on 27 February. The share price halved to 3p.
Cardiogeni (LON: CGNI) has signed a memorandum of understanding with the private office of Sheikh Al Qassimi for funding of clinical trials. A joint venture will be formed, and it will receive £20m over a period up to 2027 to complete research and clinical trials in the UAE. There will be an initial cash injection of £5m. The cash will fund phase 2b/3 clinical trials and commercialisation of Cardiogeni’s heart failure treatments. The deal could be signed by the end of March 2025. The share price slumped a further 44.4% to 25p.
Valereum (LON: VLRM) is not proceeding with the £2m option agreement with Blue Sky Ventures. Blue Sky was going to subscribe for shares at 10p each. It was previously announced that the option had been exercised. The proposed subscription may be taken on by another investor. The share price dropped 18.6% to 24p. Marula Mining (LON: MARU) has signed the first copper sales agreement for the Kinusi copper mine with a European commodity trader. The initial delivery is 250 tonnes of copper concentrate based on 20% copper grade. The income is linked to the LME copper price with additional payments for gold and silver content. The first revenues should be received in this quarter. After successfully delivery, there will be more each month that will total up to 1,000 tonnes. There are three other potential offtake agreements. Kinui has reached a milestone, so $200,000 of shares have been issued to Takela Mining Tanzania at 6p each. Marula Mining has also paid the final consideration of £625,000 for Northern Cape Lithium and Tungsten in the form of 20.83 million shares at 6p each. Modifications to the plant at the Kilifi processing plant in Kenya should be completed in the second quarter. As part of the drawdown agreement, AUO Commercial Brokerage has subscribed for £500,000 worth of shares at 3.75p/share. The share price slipped 18.4% to 5p/share.
FTSE 100 demonstates resilience amid tariff concerns
The FTSE 100 dipped marginally on Friday as corporate announcements again weighed on the index, and investors digested the latest developments from the White House.
London’s leading index was down 0.15% at the time of writing but remained within touching distance of all-time record highs.
Trump’s threat of ‘reciprocal tariffs’, which could target every trading partner based on existing tariffs on US imports and trade balances, gave investors something to think about on Friday with a potentially complex impact on global trade.
The president’s new plan risks a slowdown in activity as businesses cautiously move forward. Such a move by Trump also risks higher inflation.
Given the backdrop of uncertainty, UK investors with holdings in a selection of London’s leading shares should be content with this week’s performance as the FTSE 100 again displayed its defensive attributes and navigated a week of mixed corporate earnings and macro uncertainties.
However, a second straight day of disappointing corporate updates dragged on the index despite mining companies putting in a solid shift at the top of the leaderboard.
“Banking and pharma stocks pulled the market down, led by HSBC amid talk of more job cuts. Reducing staff numbers typically yields a positive reaction from the market as the business is saving money, yet investors might fear HSBC isn’t going hard enough with trimming its bloated headcount,” said Russ Mould, investment director at AJ Bell.
“NatWest also weighed on the FTSE as its results were solid rather than spectacular. The bank has been doing well, yet the market has already priced in that success. Investors were upset there wasn’t enough in the forward guidance to warrant large upgrades to earnings forecasts, so there was an element of profit-taking on the results.”
NatWest shares were down 2% at the time of writing while HSBC dropped 1%.
Antofagasta and Glencore were the top two risers after metals, including copper, rallied again overnight. Copper prices are 11% higher over the past month and 20% higher year-to-date.
Supply@ME Capital shares soar after appointing new auditor
Supply@ME Capital shares soared on Friday after the inventory monetisation platform announced the appointment of a new auditor.
Supply@ME Capital has appointed Bright Grahame Murray as its new auditor for the 2024 financial year, effective immediately. The appointment follows the resignation of the previous auditor, Crowe U.K., in September 2024, who resigned citing ‘risks’ of carrying out an audit of the company.
Shareholders will vote on Bright Grahame Murray’s re-appointment at the next Annual General Meeting.
The resignation of an auditor is, of course, a major red flag, and shares reacted accordingly when the resignation was announced last year. That said, the 150% rally in Supply@ME shares on Friday took the price back to around the same level they were before Crowe resigned.
SYME operates a fintech platform that provides Inventory Monetisation solutions to manufacturing and trading companies, helping them improve cash flow management. Supply@ME Capital reduced its operating losses by nearly 40% in the first half of 2024, reporting a loss of £1.4 million compared to £2.3 million in the same period last year. The improved performance stemmed from cost-cutting measures implemented in late 2023 and reduced corporate activity.
Nonetheless, the company reported negligible revenue during the period despite claiming a strong business pipeline.
NatWest shares slip on uninspiring guidance
NatWest shares have followed Barclays’ playbook, declining despite the FTSE 100 bank reporting broadly positive Q4 and full-year 2024 results.
Fourth-quarter 2024 earnings were reasonably good, with total income and profit before tax slightly exceeding expectations and net interest margin meeting estimates.
However, shares fell 2% as investors looked to 2025 and booked gains in the stock that has rallied over 100% since lows in October 2023. NatWest’s guidance for the coming year was in line with expectations, leaving investors with little reason to build on existing positions.
NatWest reported a 2024FY profit of £4.5 billion and earnings per share of 53.5 pence, marking a 12% increase from the previous year. The banking group achieved a return on tangible equity of 17.5%, demonstrating robust profitability.
The bank’s total income, excluding notable items, grew by £0.3 billion to £14.6 billion, representing a 2.2% increase compared to 2023. This growth was primarily driven by expanded deposit margins and increased lending activity. The net interest margin remained relatively stable at 2.13%, slightly higher than the previous year.
Given the economic uncertainty towards the end of 2024, investors will be more than happy with the bank’s performance.
In terms of lending and deposits, NatWest saw significant growth in its core business areas. Net loans to customers increased by £12.9 billion to £368.5 billion, with notable growth in both retail banking and commercial sectors. Customer deposits also showed healthy growth, rising by £12.2 billion to reach £431.3 billion.
The bank has also announced a final dividend of 15.5 pence per share, bringing the total dividend for 2024 to 21.5 pence, representing a 26% increase compared to 2023. Total capital distributions for the year amounted to £4.0 billion, reflecting the bank’s strong capital position and commitment to shareholder returns.
“NatWest caps off a strong year with a good set of fourth-quarter numbers that saw a slight beat on the profit line driven by higher non-interest income and better impairments,” explained Matt Britzman, senior equity analyst, Hargreaves Lansdown.
“There’s been a seismic sentiment shift over 2024, as the NatWest has moved on from its troubles at the helm and the UK banking environment has played out much better than some had feared. The setup for 2025 is one of cautious optimism, with borrowers remaining resilient, inflation in a more manageable place, and a UK economy that’s trying its hardest to squeeze out some growth.
“2025 could be the year NatWest finally sheds its government ties, with plans to return to full private ownership. After the UK government’s failed attempt to sell its stake earlier in 2024, this news will be a welcome development for investors who have long been waiting for the bank to regain its full independence.”

